Drugs & Targets FDA issues guidance on implementing decentralized elements in clinical trials September 20, 2024Vol.50 No.35
Drugs & Targets FDA issues guidance on integrating randomized controlled trials into routine clinical practice September 20, 2024Vol.50 No.35
Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies September 13, 2024Vol.50 No.34By McKenzie Prillaman
Drugs & Targets FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy September 13, 2024Vol.50 No.34
Drugs & Targets FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas September 13, 2024Vol.50 No.34
Drugs & Targets FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee September 13, 2024Vol.50 No.34
Drugs & Targets FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC September 06, 2024Vol.50 No.33
Drugs & Targets FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC September 06, 2024Vol.50 No.33
Drugs & Targets FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC September 06, 2024Vol.50 No.33
